Prognostic value of the liver fibrosis marker fibrosis‐5 index in patients with acute heart failure

Autor: Daichi Maeda, Yumiko Kanzaki, Kazushi Sakane, Kosuke Tsuda, Kanako Akamatsu, Ryoto Hourai, Takahiro Okuno, Daisuke Tokura, Sayuri Nakayama, Hitomi Hasegawa, Hideaki Morita, Takahide Ito, Masaaki Hoshiga
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: ESC Heart Failure, Vol 9, Iss 2, Pp 1380-1387 (2022)
Druh dokumentu: article
ISSN: 2055-5822
DOI: 10.1002/ehf2.13829
Popis: Abstract Aims Recently, liver fibrosis markers, such as the fibrosis‐4 index (FIB‐4), have been shown to be associated with prognosis in patients with heart failure. The fibrosis‐5 (FIB‐5) index, which assesses albumin, alkaline phosphatase, aspartate transaminase, alanine aminotransferase and platelet count, is a simple liver fibrosis marker that was reported to be superior to FIB‐4 for differentiation of liver fibrosis. This study aimed to compare the prognostic value of FIB‐4 and FIB‐5 in patients with heart failure. Methods and results The FIB‐4 and FIB‐5 scores were calculated at discharge in 906 patients hospitalized with heart failure. The patients were stratified into three groups based on their FIB‐5 scores: low (n = 303), middle (n = 301), and high (n = 302) FIB‐5 groups. The primary endpoint was a composite of cardiac death or rehospitalization for heart failure. The low FIB‐5 group was older and had larger inferior vena cava diameters and higher brain natriuretic peptide levels than the other two groups. The primary endpoint occurred in 156 (51.5%), 110 (36.5%), and 54 patients (17.9%) in the low, middle, and high FIB‐5 groups, respectively (P
Databáze: Directory of Open Access Journals